64th ASH Annual Meeting and Exposition: Standard Treatments Face Challenges
Standard treatments face challenges with new evidence. This time at the 64th ASH meeting, two drugs for blood cancers, Blinatumomab and Zanubrutinib, revealed their latest data from clinical trials in the Selected Latest Breaking Abstract section. It also presents the early results of the first-in-class drug Iptacopan for the rare disease paroxysmal nocturnal hemoglobinuria. One of the speeches in this session gave a good example. Dr. Saskia Middeldorp presented that heparin has no benefit in raising the live birth rate in inherited thrombophilia women with recurrent miscarriages. Previously, heparin injection was a standard treatment for women with recurrent miscarriage inherited thrombophilia, but without randomized controlled studies to prove the effectiveness.
BIODND – An AI-Powered Database That Breaks New Ground in Life Science Business Development
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence